Skip to main content
NCBI home page
Gut logoLink to Gut
. 1988 Nov;29(11):1569–1577. doi: 10.1136/gut.29.11.1569

Prevention of acute gastric erosions in the rat by novel semi-synthetic amphipathic analogues of pepstatin.

S P Huddy 1, G Patel 1, G C Heywood 1, B M Austen 1, J Hermon-Taylor 1
PMCID: PMC1433831  PMID: 3209115

Abstract

Pepstatin is a potent aspartyl proteinase inhibitor which is virtually insoluble in physiological media. Five semi-synthetic amphipathic analogues of pepstatin, prepared by N terminal substitution of native pepstatin with hydrophilic oligopeptides, have been assessed for their ability to protect the mucosa in two animal models of acute gastric erosions. Concentrations of approximately 90 pmol/mg were achieved in the rat gastric mucosa after oral administration of a 20 mmol solution. These levels are theoretically adequate to inhibit all pepsin like proteinase activity (including zymogens). Each pepstatin analogue was tested by intragastric administration in a controlled hypotension/luminal acid animal model of acute gastric erosions in a group of six animals. All the inhibitors tested produced marked mucosal protection, as measured by a mucosal damage index, compared with control animals (control mean 241, range 100-420; Pepstatinyl-Gly-Orn-Orn-Cys (10 mmol) mean 3, range 0-8, p less than 0.01; Pepstatinyl-Gly-Cysteic acid-Cysteic acid (10 mmol) mean 5, range 0-21, p less than 0.01; Pepstatinyl-Gly-Lys-Lys (10 mmol) mean 18, range 0-60, p less than 0.01; Pepstatinyl-Gly-Cysteic acid-Cysteic acid (1 mmol) mean 24, range 0-86, p less than 0.01; Pepstatinyl-Gly-Orn-Orn-Cys (1 mmol) mean 57, range 0-116, p less than 0.01; Pepstatinyl-Gly-Asp-Asp (1 mg/ml suspension) mean 68, range 19-126, p less than 0.01; Pepstatinyl-Arg-OMe (1 mmol) mean 93, range 4-142, p less than 0.05, Pepstatinyl-Gly-Lys-Lys (1 mmol) mean 157, range 70-286, NS). In a platelet activating factor/20% luminal ethanol model of erosions the pepstatin analogues again provided mucosal protection although this only reached statistical significance for one of three compounds tested.

Full text

PDF
1569

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ANDERSON W., SOMAN P. D. DEGRADED CARRAGEENAN AND EXPERIMENTAL ACUTE GASTRIC ULCERATION IN THE GUINEA PIG. Nature. 1963 Jul 27;199:389–389. doi: 10.1038/199389a0. [DOI] [PubMed] [Google Scholar]
  2. Alphin R. S., Vokac V. A., Gregory R. L., Bolton P. M., Tawes J. W., 3rd Role of intragastric pressure, pH, and pepsin in gastric ulceration in the rat. Gastroenterology. 1977 Sep;73(3):495–500. [PubMed] [Google Scholar]
  3. Aoyagi T., Morishima H., Nishizawa R., Kunimoto S., Takeuchi T. Biological activity of pepstatins, pepstanone A and partial peptides on pepsin, cathepsin D and renin. J Antibiot (Tokyo) 1972 Dec;25(12):689–694. doi: 10.7164/antibiotics.25.689. [DOI] [PubMed] [Google Scholar]
  4. BEIL A. R., Jr, MANNIX H., Jr, BEAL J. M. MASSIVE UPPER GASTROINTESTINAL HEMORRHAGE AFTER OPERATION. Am J Surg. 1964 Sep;108:324–330. doi: 10.1016/0002-9610(64)90346-0. [DOI] [PubMed] [Google Scholar]
  5. BIANCHI R. G., COOK D. L. ANTIPEPTIC AND ANTIULCEROGENIC PROPERTIES OF A SYNTHETIC SULFATED POLYSACCHARIDE (SN-263). Gastroenterology. 1964 Oct;47:409–414. [PubMed] [Google Scholar]
  6. Baron J. H., Gribble R. J., Holdstock D. J., Misiewicz J. J. Double-blind controlled trial of amylopectin sulphate (Depepsen) in the symptomatic treatment of duodenal ulcer. Gut. 1977 Sep;18(9):723–724. doi: 10.1136/gut.18.9.723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bonnevie O., Svendsen L. B., Holst-Christensen J., Johansen T. S., Søltoft J., Christiansen P. M. Double-blind randomised clinical trial of a pepsin-inhibitory pentapeptide (pepstatin) in the treatment of duodenal ulcer. Gut. 1979 Jul;20(7):624–628. doi: 10.1136/gut.20.7.624. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Czaja A. J., McAlhany J. C., Pruitt B. A., Jr Acute gastroduodenal disease after thermal injury. An endoscopic evaluation of incidence and natural history. N Engl J Med. 1974 Oct 31;291(18):925–929. doi: 10.1056/NEJM197410312911801. [DOI] [PubMed] [Google Scholar]
  9. Fogelman M. J., Garvey J. M. Acute gastroduodenal ulceration incident to surgery and disease. Analysis and review of eighty-eight cases. Am J Surg. 1966 Nov;112(5):651–656. doi: 10.1016/0002-9610(66)90098-5. [DOI] [PubMed] [Google Scholar]
  10. Ford T. F., Grant D. A., Austen B. M., Hermon-Taylor J. Intramucosal activation of pepsinogens in the pathogenesis of acute gastric erosions and their prevention by the potent semisynthetic amphipathic inhibitor pepstatinyl-glycyl-lysyl-lysine. Clin Chim Acta. 1985 Jan 15;145(1):37–47. doi: 10.1016/0009-8981(85)90017-8. [DOI] [PubMed] [Google Scholar]
  11. Ford T. F., Hermon-Taylor J., Grant D. A. A sensitive fluorometric assay for the simultaneous estimation of pepsin and pepsinogen in gastric mucosa. Clin Chim Acta. 1982 Nov 24;126(1):17–23. doi: 10.1016/0009-8981(82)90358-8. [DOI] [PubMed] [Google Scholar]
  12. Goodman A. A., Frey C. F. Massive upper gastrointestinal hemorrhage following surgical operations. Ann Surg. 1968 Feb;167(2):180–184. doi: 10.1097/00000658-196802000-00004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Halloran L. G., Zfass A. M., Gayle W. E., Wheeler C. B., Miller J. D. Prevention of acute gastrointestinal complications after severe head injury: a controlled trial of cimetidine prophylaxis. Am J Surg. 1980 Jan;139(1):44–48. doi: 10.1016/0002-9610(80)90228-7. [DOI] [PubMed] [Google Scholar]
  14. Kamada T., Fusamoto H., Kawano S., Noguchi M., Hiramatsu K. Gastrointestinal bleeding following head injury: a clinical study of 433 cases. J Trauma. 1977 Jan;17(1):44–47. [PubMed] [Google Scholar]
  15. Kivilaakso E., Fromm D., Silen W. Relationship between ulceration and intramural pH of gastric mucosa during hemorrhagic shock. Surgery. 1978 Jul;84(1):70–78. [PubMed] [Google Scholar]
  16. Kivilaakso E., Silen W. Pathogenesis of experimental gastric-mucosal injury. N Engl J Med. 1979 Aug 16;301(7):364–369. doi: 10.1056/NEJM197908163010707. [DOI] [PubMed] [Google Scholar]
  17. Lucas C. E., Sugawa C., Riddle J., Rector F., Rosenberg B., Walt A. J. Natural history and surgical dilemma of "stress" gastric bleeding. Arch Surg. 1971 Apr;102(4):266–273. doi: 10.1001/archsurg.1971.01350040028006. [DOI] [PubMed] [Google Scholar]
  18. Mangla J. C., Kim Y. M., Turner M. D. Are pepsinogens activated in gastric mucosa after aspirin-induced injury? Experientia. 1974 Jul 15;30(7):727–729. doi: 10.1007/BF01924151. [DOI] [PubMed] [Google Scholar]
  19. Martin L. F., Staloch D. K., Simonowitz D. A., Dellinger E. P., Max M. H. Failure of cimetidine prophylaxis in the critically ill. Arch Surg. 1979 Apr;114(4):492–496. doi: 10.1001/archsurg.1979.01370280146023. [DOI] [PubMed] [Google Scholar]
  20. Ohe K., Ueno N., Yokoya H., Miyoshi A. The activation of pepsinogen inside the gastric mucosa caused by the hydrogen ion back diffusion during the course of aspirin ulceration. Hiroshima J Med Sci. 1979 Mar;28(1):1–11. [PubMed] [Google Scholar]
  21. Ohe K., Yokoya H., Kitaura T., Kunita T., Miyoshi A. Increase in pepsin content in gastric mucosa during the course of aspirin- and taurocholate-induced gastric ulceration in rats. Dig Dis Sci. 1980 Nov;25(11):849–856. doi: 10.1007/BF01338527. [DOI] [PubMed] [Google Scholar]
  22. Priebe H. J., Skillman J. J., Bushnell L. S., Long P. C., Silen W. Antacid versus cimetidine in preventing acute gastrointestinal bleeding. A randomized trial in 75 critically ill patients. N Engl J Med. 1980 Feb 21;302(8):426–430. doi: 10.1056/NEJM198002213020802. [DOI] [PubMed] [Google Scholar]
  23. Pruitt B. A., Jr, Foley F. D., Moncrief J. A. Curling's ulcer: a clinical-pathology study of 323 cases. Ann Surg. 1970 Oct;172(4):523–539. doi: 10.1097/00000658-197010000-00001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Rosam A. C., Wallace J. L., Whittle B. J. Potent ulcerogenic actions of platelet-activating factor on the stomach. Nature. 1986 Jan 2;319(6048):54–56. doi: 10.1038/319054a0. [DOI] [PubMed] [Google Scholar]
  25. Skillman J. J., Bushnell L. S., Goldman H., Silen W. Respiratory failure, hypotension, sepsis, and jaundice. A clinical syndrome associated with lethal hemorrhage from acute stress ulceration of the stomach. Am J Surg. 1969 Apr;117(4):523–530. doi: 10.1016/0002-9610(69)90011-7. [DOI] [PubMed] [Google Scholar]
  26. Stothert J. C., Jr, Simonowitz D. A., Dellinger E. P., Farley M., Edwards W. A., Blair A. D., Cutler R., Carrico C. J. Randomized prospective evaluation of cimetidine and antacid control of gastric pH in the critically ill. Ann Surg. 1980 Aug;192(2):169–174. doi: 10.1097/00000658-198008000-00006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Umezawa H., Aoyagi T., Morishima H., Matsuzaki M., Hamada M. Pepstatin, a new pepsin inhibitor produced by Actinomycetes. J Antibiot (Tokyo) 1970 May;23(5):259–262. doi: 10.7164/antibiotics.23.259. [DOI] [PubMed] [Google Scholar]
  28. Umezawa H. Structures and activities of protease inhibitors of microbial origin. Methods Enzymol. 1976;45:678–695. doi: 10.1016/s0076-6879(76)45058-9. [DOI] [PubMed] [Google Scholar]
  29. Zimmon D. S., Miller G., Cox G., Tesler M. A. Specific inhibition of gastric pepsin in the treatment of gastric ulcer. Gastroenterology. 1969 Jan;56(1):19–23. [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES